IP Library Granted Patent US 6,852,690
Granted Patent B1
US 6,852,690 · App. 09/011,940 · Granted Feb 8, 2005

Method and composition for enhanced parenteral nutrition

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,852,690
App. No.
09/011,940
Granted
Feb 8, 2005
Kind
B1
Abstract

A composition and method for improved parenteral administration of nutrients is provided. The method comprises co-administration of nutrients, especially carbohydrates, and an insulinotropic peptide, or its derivatives, analogs, and fragments. The method and composition provide high carbohydrate nutrition while avoiding hyper- and hypoglycemia and their attendant deleterious effects.

Claims (7)

1. A method of enhancing metabolism of nutrients, comprising administering by a parenteral route to a non-diabetic patient in need of enhancing metabolism of nutrients a nutritively effective amount of one or more nutrients or any combination thereof and one or more insulinotropic peptide or peptides, wherein said peptide or peptides is GLP-1, GLP-1 (7-34), GLP-1 (7-35), GLP-1 (7-36), GLP (7-37), the deletion sequences thereof, the natural and non-natural amino acid residue substitutes thereof, the C-terminus carboxamides thereof, the C-terminus esters thereof, the C-terminus ketones thereof, the N-terminus modifications thereof, or any mixture thereof.

2. A method of enhancing metabolism of nutrients, comprising administering by a parenteral route to a patient with a disturbed glucose metabolism, a surgery patient, a comatose patient, a patient in shock, a patient with gastrointestinal disease, a patient with digestive hormone disease, an obese patient, an atherosclerotic patient, a patient with vascular disease, a patient with gestational diabetes, a patient with liver disease, a patient with liver cirrhosis, a patient with glucocorticoid excess, a patient with Cushings disease, a patient with activated counterregulatory hormones that occur after trauma or a disease, a patient with hypertriglyceridemia, or a patient with chronic pancreatitis, a nutritively effective amount of one or more nutrients or any combination thereof and one or more insulinotropic peptides.

3. The method of claim 1 , wherein said insulinotropic peptide or peptides is GLP-1(7-36) amide.

4. A method of enhancing metabolism of nutrients, comprising administering by a parenteral route to a patient in need of enhancing metabolism of nutrients a nutritively effective amount of glucose and one or more insulinotropic peptide or peptides, wherein said insulinotropic peptide or peptides is GLP-1, GLP-1 (7-34), GLP-1 (7-35), GLP-1 (7-36), GLP (7-37), the deletion sequences thereof, the natural and non-natural amino acid residue substitutes thereof, the C-terminus carboxamides thereof, the C-terminus esters thereof, the C-terminus ketones thereof, the N-terminus modifications thereof, or any mixture thereof; wherein the administration of the nutrient(s) produces a blood glucose level in the patient of from about 80 to 180 mg glucose per deciliter of blood, and the rate of administration is calculated to deliver up to about 1000 g of glucose or its equivalent per patient per day.

5. The method of claim 1 wherein said nutrient is one or more amino acids, lipids free fatty acids, mono- or diglycerides or glycerol, or any combination thereof.

6. A method for non-alimentary nutrition comprising administering by a parenteral route to a patient in need of parenteral nutrition, a nutritively effective amount of one or more nutrients selected from the group consisting of carbohydrates, ammo acids, lipids, free fatty acids, mono-or diglycerides, glycerol and any combination thereof; and one or more insulinotropic peptides, wherein the insulinotropic peptide is GLP-1, wherein the administration of the nutrient(s) produces a blood glucose level in the patient of from about 80 to 180 mg glucose per deciliter of blood, and the rate of administration is calculated to deliver up to about 1000 g of glucose or its equivalent per patient per day.

7. The method of claim 1 wherein the insulinotropic peptide is an exendin.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2003
From: NAUCK, MICHAEL A.
To: BIONEBRASKA AKA RESTORAGEN, INC.
Reel/Frame 014347/0295 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2003
From: BIONEBRASKA, INC., A/K/A RESTORAGEN, INC.
To: AMYLIN PHARMACEUTICALS, INC.
Reel/Frame 013729/0378 →
SECURITY INTEREST Recorded Dec 18, 2001
From: RESTORAGEN, INC., F/K/A BIONEBRASKA, INC.
To: MEDTRONIC INTERNATIONAL, LTD.
Reel/Frame 012350/0779 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 1998
From: NAUCK, MICHAEL A.
To: BIONEBRASKA, INC.
Reel/Frame 009470/0646 →